Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016057915) SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2016/057915 International Application No.: PCT/US2015/054933
Publication Date: 14.04.2016 International Filing Date: 09.10.2015
IPC:
A61K 47/10 (2006.01) ,A61K 47/26 (2006.01) ,A61K 9/107 (2006.01) ,A61K 31/202 (2006.01) ,A61K 31/232 (2006.01) ,A61P 9/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
08
containing oxygen
10
Alcohols; Phenols; Salts thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
26
Carbohydrates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
10
Dispersions; Emulsions
107
Emulsions
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
20
having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
202
having three or more double bonds, e.g. linolenic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
22
of acyclic acids, e.g. pravastatin
23
of acids having a carboxyl group bound to a chain of seven or more carbon atoms
232
having three or more double bonds, e.g. etretinate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
Applicants:
SANCILIO & COMPANY, INC. [US/US]; 3874 Fiscal Court, Suite 200 Riviera Beach, Florida 33404, US
Inventors:
SANCILIO, Frederick D.; US
THORSTEINSSON, Thorsteinn; US
DANIEL-ARCHIBALD, Glynis; US
LOPEZ-TOLEDANO, Miguel; US
DAAK, Ahmed Abd Almalik Ahmed Mohammed; US
Agent:
MILLS, E. Eric; US
Priority Data:
62/062,63410.10.2014US
62/062,63810.10.2014US
62/062,64310.10.2014US
62/062,64610.10.2014US
62/062,65110.10.2014US
62/062,65210.10.2014US
Title (EN) SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES
(FR) COMPOSITIONS D'ACIDES GRAS ET D'ESTERS D'ACIDES GRAS AUTO-MICELLISANTES, AINSI QUE LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS PATHOLOGIQUES
Abstract:
(EN) Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.
(FR) L'invention concerne des compositions contenant au moins un acide gras oméga 3 (sous la forme de triglycéride, d'ester ou d'ester d'acide gras libre) et au moins un agent tensioactif ; les compositions formant des micelles lorsqu'elles sont en contact avec un milieu aqueux. L'invention concerne également des méthodes d'administration à un patient d'une composition contenant au moins un acide gras oméga 3 (sous la forme de triglycéride, d'ester ou d'ester d'acide gras libre) et au moins un agent tensioactif, les compositions formant des micelles lorsqu'elles sont en contact avec un milieu aqueux, la biodisponibilité de l'acide gras oméga 3 étant sensiblement indépendante d'un effet alimentaire. Les compositions selon l'invention sont utiles dans le traitement de certains états pathologiques pouvant comprendre les syndromes de malabsorption (1), la cholangite sclérosante primitive (CSP) (2), la stéatose hépatique non alcoolique (SHNA) (3), la drépanocytose (4), la dégénérescence maculaire liée à l'âge (DMLA) (5) et les maladies neurodégénératives (6), notamment la maladie de Parkinson (MP), la maladie d'Alzheimer (MA), la sclérose latérale amyotrophique (SLA ou maladie de Lou Gehrig), l'épilepsie, le syndrome bipolaire, les lésions cérébrales traumatiques, la neuropathie périphérique et la sclérose en plaques (SP). L'invention concerne également diverses formes galéniques pour l'administration des compositions, ainsi que l'utilisation de ces compositions dans des aliments fonctionnels. L'invention concerne encore des kits contenant des instructions d'administration de ces compositions.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)